The gist: In a clinical trial, patients with stage IV metastatic melanoma had better responses to treatment with vemurafenib (Zelboraf) if they received immunotherapy drugs beforehand than if they received chemotherapy or “kinase inhibitor” drugs beforehand.
“Prior treatment appeared to considerably affect how patients with stage IV metastatic melanoma responded to vemurafenib therapy, according to study results.
“Those who had undergone prior treatment with immunotherapy demonstrated better outcomes with vemurafenib (Zelboraf, Hoffmann-La Roche) than those who underwent prior treatment with chemotherapy or kinase inhibitors, results showed…
“ ‘Our data demonstrate that the type of pretreatment strongly influences the outcome of vemurafenib therapy, with a precedent immunotherapy showing a positive, and a prior chemotherapy and kinase inhibitors showing a negative impact on survival, respectively,’ Ugurel and colleagues wrote. ‘Moreover, we show that the patient’s overall performance status, serum LDH, age and gender independently impact vemurafenib therapy outcome. These findings should be taken into account for future design of therapy sequencing in BRAF V600 mutation-positive melanoma patients.’ ”